Aminoglycosides for the treatment of gram-negative infections: therapeutic use, resistance and future outlook

Finland, 1946, Development of streptomycin resistance during treatment, J Am Med Assoc, 132, 16, 10.1001/jama.1946.02870360018005 Shaw, 1993, Molecular genetics of aminoglycoside resistance genes and familial relationships of the aminoglycoside-modifying enzymes, Microbiol Rev, 57, 138, 10.1128/MR.57.1.138-163.1993 Rather, 1998, Origins of the aminoglycoside modifying enzymes, Drug Resistance Updates, 1, 285, 10.1016/S1368-7646(98)80044-7 Brisson-Noel, 1988, Evidence for natural gene transfer from gram-positive cocci to Escherichia coli, J Bacteriol, 170, 1739, 10.1128/jb.170.4.1739-1745.1988 Macinga, 1995, Identification and analysis of aarP, a transcriptional activator of the 2′-N-acetyltransferase in Providencia stuartii, J Bacteriol, 177, 3407, 10.1128/jb.177.12.3407-3413.1995 Miller, 1997, The most frequent aminoglycoside resistance mechanisms – changes with time and geographic area: A reflection of aminoglycoside usage patterns, Clin Infect Dis, 24(suppl1), S46, 10.1093/clinids/24.Supplement_1.S46 The Surveillance NetworkTM(TSN) Database, – U. S. A. MRL Pharmaceutical Services, Herndon, Virginia. Web site [email protected]. Schifman, 1998, Cumulative Antimicrobial Susceptibility Patterns 98–04, Data analysis and critique. College of American Pathologists, Hanberger, 1999, Antibiotic susceptibility among aerobic gram-negative bacilli in intensive care units in five European countries, J Am Med Assoc, 281, 67, 10.1001/jama.281.1.67 Edison, 1991, The aminoglycosides, Mayo Clin Proc, 66, 1158, 10.1016/S0025-6196(12)65798-X Gilbert, 1991, Once daily aminoglycoside therapy, Antimicrob Agents Chemother, 35, 399, 10.1128/AAC.35.3.399 Emerging Infections (EIN) of the Infections Diseases Society of America. Clin Inf Dis 1999; Vol 28: CIB Hot Page. Bryan, 1983, Analysis of 1186 episodes of gram negative bacteremia in non-university hospitals: the effects of antimicrobial therapy, Rev Infect Dis, 5, 629, 10.1093/clinids/5.4.629 Kreger, 1980, Gram negative bactermia, Am J Med, 68, 332, 10.1016/0002-9343(80)90101-1 Uzun, 1992, Factors influencing prognosis in bacteremia due to gram negative organisms: evaluation of 448 episodes in a Turkish university hospital, Clin Infect Dis, 15, 866, 10.1093/clind/15.5.866 Torres, 1990, Incidence, risk and prognosis factors of nosocomial pneumonia in mechanically ventilated patients, Am Rev Resp Dis, 142, 523, 10.1164/ajrccm/142.3.523 Schimpff, 1971, empiric therapy with carbenicillin and gentamicin for febrile patients with cancer and granulocytopenia, N Engl J Med, 284, 1061, 10.1056/NEJM197105132841904 Klastersky, 1977, Significant of antimicrobial synergism for the outcome of gram negative sepsis, Am J Med Sci, 273, 157, 10.1097/00000441-197703000-00005 Scott, 1976, Synergistic activity of carbenicillin and gentamicin in experimental pseudomonas bacteremia in neutropenic rats, Antimicrob Agents Chemother, 10, 646, 10.1128/AAC.10.4.646 Baltch, 1985, Combinations of antibiotics against Pseudomonas aeruginosa, Am J Med, 79(suppl 1A), 8, 10.1016/0002-9343(85)90185-8 Levin, 1981, Antibiotics of choice in suspected sepsis, J Antimicrob Chemother, 8 (Suppl A), 133, 10.1093/jac/8.suppl_A.133 Young, 1984, Aminoglycosides in combination therapy, Chemoterapia, 3 (suppl), 38 Zinner, 1985, Review of amikacin usage in the EORTC trials, Am J Med, 79 (supl 1A), 17, 10.1016/0002-9343(85)90186-X Commetta, 1994, Prospective randomized comparison of imipenem monotherapy with imipenem plus netilmicin for treatment of severe infections in nonneutropenic patients, Antimicrob Agents Chemother, 38, 1309, 10.1128/AAC.38.6.1309 Collins, 1991, Aminoglycosides versus beta-lactams in gram-negative pneumonia, Sem Resp Infect, 6, 136 Craig, 1997, Aminoglycosides are useful for severe respiratory tract infections, Sem Resp Infect, 12, 271 Chow, 1991, Enterobacter bacteremia: clinical features and emergence of antibiotic resistance during therapy, Ann Int Med, 115, 585, 10.7326/0003-4819-115-8-585 Korvick, 1992, Prospective observational study of Klebsiella bactermia in 230 patients: outcome for antibiotic combinations versus monotherapy, Antimicrob Agents Chemother, 36, 2639, 10.1128/AAC.36.12.2639 Hilf, 1989, Antibiotic therapy for Pseudomonas aeruginosa bacteremia: outcome correlation in a prospective study of 200 patients, Am J Med, 87, 540, 10.1016/S0002-9343(89)80611-4 1987, N Engl J Med, 317, 1692, 10.1056/NEJM198712313172703 Bodey, 1985, Pseudomonas bacteremia, Retrospective analysis of 410 episodes. Arch Intern Med, 145, 1621, 10.1001/archinte.1985.00360090089015 Milatovic, 1987, Development of resistance during antibiotic therapy, Eur J Clin Microbiol, 6, 234, 10.1007/BF02017607 Fish, 1995, Development of resistance during antimicrobial therapy: a review of antibiotic classes and patient characteristics in 173 studies, Pharmacotherapy, 15, 279, 10.1002/j.1875-9114.1995.tb04366.x Nichols, 1985, The emergence of resistance to beta-lactam antibiotics during treatment of Pseudomonas aeruginosa lower respiratory tract infections: is combination therapy the solution?, Chemoterapia, 4, 102 Pechere, 1988, Emergence of resistance during beta-lactam therapy of gram negative infections: bacterial mechanisms and medical responses, Drugs, 35 (suppl 2), 22, 10.2165/00003495-198800352-00007 Michea-Hamzehpour, 1986, Combination therapy: a way to limit emergence of resistance?, Am J Med, ;138, 10.1016/0002-9343(86)90491-2 Dejace, 1986, Comparative review of combination therapy: two beta-lactams vs beta-lactam plus aminoglycoside, Am J Med, 80 (suppl 6B), 29, 10.1016/0002-9343(86)90476-6 Stratton, 1989, Comparison of the bactericidal activity of ciprofloxacin alone and in combination with selected antipseudomonal β-lactam agents against clinical isolates of Pseudomonas aeruginosa, Diagn Microbiol Infect Dis, 11, 41, 10.1016/0732-8893(88)90072-7